These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 22496388)
21. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Wang J; Barnes RO; West NR; Olson M; Chu JE; Watson PH Breast Cancer Res; 2008; 10(3):R51. PubMed ID: 18534028 [TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Haim K; Weitzenfeld P; Meshel T; Ben-Baruch A Neoplasia; 2011 Mar; 13(3):230-43. PubMed ID: 21390186 [TBL] [Abstract][Full Text] [Related]
23. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Adams BD; Cowee DM; White BA Mol Endocrinol; 2009 Aug; 23(8):1215-30. PubMed ID: 19423651 [TBL] [Abstract][Full Text] [Related]
24. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459 [TBL] [Abstract][Full Text] [Related]
25. Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. Peng J; Jordan VC Int J Oncol; 2010 Feb; 36(2):451-8. PubMed ID: 20043081 [TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. Banerjee S; Sengupta K; Saxena NK; Dhar K; Banerjee SK Mol Cancer Res; 2005 Mar; 3(3):151-62. PubMed ID: 15798095 [TBL] [Abstract][Full Text] [Related]
27. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells. Kavarthapu R; Dufau ML Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112 [TBL] [Abstract][Full Text] [Related]
28. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091 [TBL] [Abstract][Full Text] [Related]
29. ER-mediated anti-tumor effects of shikonin on breast cancer. Yang Y; Gao W; Tao S; Wang Y; Niu J; Zhao P; Rao C; Yang L Eur J Pharmacol; 2019 Nov; 863():172667. PubMed ID: 31545985 [TBL] [Abstract][Full Text] [Related]
30. Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. Spanheimer PM; Lorenzen AW; De Andrade JP; Kulak MV; Carr JC; Woodfield GW; Sugg SL; Weigel RJ Ann Surg Oncol; 2015 Dec; 22(13):4287-94. PubMed ID: 25971960 [TBL] [Abstract][Full Text] [Related]
31. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379 [TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Thrane S; Lykkesfeldt AE; Larsen MS; Sorensen BS; Yde CW Breast Cancer Res Treat; 2013 May; 139(1):71-80. PubMed ID: 23609470 [TBL] [Abstract][Full Text] [Related]
33. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Garcia R; Franklin RA; McCubrey JA Cell Cycle; 2006 Aug; 5(16):1840-6. PubMed ID: 16861904 [TBL] [Abstract][Full Text] [Related]
34. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027 [TBL] [Abstract][Full Text] [Related]
35. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chun J; Kim YS Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902 [TBL] [Abstract][Full Text] [Related]
36. Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines. Tan H; Zhong Y; Pan Z BMC Cancer; 2009 Jan; 9():31. PubMed ID: 19171042 [TBL] [Abstract][Full Text] [Related]
37. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha. Weitsman GE; Weebadda W; Ung K; Murphy LC Breast Cancer Res Treat; 2009 Nov; 118(2):269-79. PubMed ID: 18941890 [TBL] [Abstract][Full Text] [Related]
38. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients. Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328 [TBL] [Abstract][Full Text] [Related]
39. VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo. Van Themsche C; Parent S; Leblanc V; Descôteaux C; Simard AM; Bérubé G; Asselin E Endocr Relat Cancer; 2009 Dec; 16(4):1185-95. PubMed ID: 19661132 [TBL] [Abstract][Full Text] [Related]
40. Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling. Wang C; Xu CX; Bu Y; Bottum KM; Tischkau SA Carcinogenesis; 2014 Mar; 35(3):703-13. PubMed ID: 24163404 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]